
vulnerable cohort, a Best Practice Statement in line
with the ESVS and ADA recommendations was
made.129,137 It should be noted that in the COMPASS trial
in addition to a high bleeding risk of rivaroxaban, other
exclusion criteria included end stage renal disease, severe heart failure, recent stroke, history of haemorrhagic
or lacunar stroke, and poor life expectancy.138 A network
meta-analysis showed no superiority